Advertisement
Advertisement
FDMT
4D Molecular Therapeutics, Inc. Common Stock
13.33
USDSponsored
+0.63
+4.96%
Oct 09, 16:00 UTC -4
Closed
After-Market
13.31
-0.02
-0.11%
FDMT Earnings Reports
Positive Surprise Ratio
FDMT beat 15 of 23 last estimates.
65%
Next Report
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$2.49M
/-$1.06
Implied change from Q2 26 (Revenue/ EPS)
-34.10%
/+1.92%
Implied change from Q3 25 (Revenue/ EPS)
+2668.57%
/+4.95%
4D Molecular Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 13, 2026, FDMT reported earnings of -1.04 USD per share (EPS) for Q2 26, missing the estimate of -1.03 USD, resulting in a -0.29% surprise. Revenue reached 3.78 million, compared to an expected 3.16 million, with a 19.58% difference. The market reacted with a +4.64% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of -1.06 USD, with revenue projected to reach 2.49 million USD, implying an increase of 1.92% EPS, and decrease of -34.10% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
NanoViricides Inc.
Report Date
Sep 28, 2026 For Q4 26
Estimate
-$0.10
Actual
-$0.10
Surprise
+1.96%
FAQ
What were 4D Molecular Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, 4D Molecular Therapeutics, Inc. Common Stock reported EPS of -$1.04, missing estimates by -0.29%, and revenue of $3.78M, 19.58% above expectations.
How did the market react to 4D Molecular Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 4.64%, changed from $11.65 before the earnings release to $12.19 the day after.
When is 4D Molecular Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for 4D Molecular Therapeutics, Inc. Common Stock's next earnings report?
Based on 5
analysts, 4D Molecular Therapeutics, Inc. Common Stock is expected to report EPS of -$1.06 and revenue of $2.49M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.